Medical Aspects of Chemical Warfare (2008) - The Black Vault

More documents

Recommendations

Info

Medical Diagnostics136. Izraeli S, Israeli A, Danon Y. Pharmacological treatment of cyanide poisoning. Harefuah. 1988;114:338–342.137. Kirk RL, Stenhouse NS. Ability to smell solutions of potassium cyanide. Nature. 1953;171:698–699.138. Warburg O. Inhibition of the action of prussic acid in living cells. Hoppe-Seyler’s Z Physiol Chem. 1911;76:331–346.139. Keilin D. Cytochrome and respiratory enzymes. Proc R Soc Lond B Biol Sci. 1929;104:206–251.140. DiPalma JR. Noxious gases and vapers: I. Carbon monoxide, cyanide, methemoglobin, and sulfhemoglobin. In: DrillsPharmacology in Medicine. New York, NY: McGraw-Hill; 1971: 1189–1205.141. Way JL. Cyanide intoxication and its mechanism of antagonism. Annu Rev Pharmacol Toxicol. 1984;24:451–481.142. Farooqui MY, Ahmed AE. Molecular interaction of acrylonitrile and potassium cyanide with rat blood. Chem BiolInteract. 1982;38:145–159.143. Blakley RL, Coop IE. The metabolism and toxicity of cyanides and cyanogenic blycosides in sheep. NZ J Sci Technol.1949;31A(3):1–16.144. Wood JL, Cooley SL. Detoxification of cyanide by cystine. J Biol Chem. 1956;218:449–457.145. Smith RP. Toxic responses of the blood. In: Casarett LJ, Amdur MO, Doull J, Klaassen CD, eds. Casarett & Doull’sToxicology: The Basic Science of Poisons. 10th ed. McGraw-Hill; 1995: 335–354.146. Ansell M, Lewis FA. A review of cyanide concentrations found in human organs. A survey of literature concerningcyanide metabolism, ‘normal’, non-fatal, and fatal cyanide levels. J Forensic Med.1970;17:148–155.147. Seto Y. Stability and spontaneous production of blood cyanide during heating. J Forensic Sci. 1996;41:465–468.148. Ballantyne C. Artifacts in the definition of toxicity by cyanides and cyanogens. Fundam Appl Toxicol. 1983;3:400-408.149. Mathur BB, Krishna G. Toxicodynamics of phosgene. In: Somani S, ed. Chemical Warfare Agents. San Diego, Calif:Academic Press, Inc; 1992: 237–254.150. Malveda M. CEH Product review: phosgene. In: SRI International. Chemical Economics Handbook. Menlo Park, Calif:SRI International; 2003: 687.151. Focused on phosgene. Chemistry Business. 2002;30–31.152. Sartori M. The War Gases. New York, NY: D Van Nostrand; 1939.153. Parshall, GW. Trends in processing and manufacturing that will affect implementation of the Chemical WeaponsConvention. Pure Appl Chem. 2002;74:2259–2263.154. Diller WF. Medical phosgene problems and their possible solution. J Occup Med. 1978;20:189–193.155. US National Research Council Committee on Toxicology. Emergency and Continuous Exposure Limits for Selected AirborneContaminants. Vol 1. Washington, DC: National Academy Press; 1984.156. Borak J, Diller WF. Phosgene exposure: mechanisms of injury and treatment strategies. J Occup Environ Med. 2001;43:110–119.157. Diller WF. Pathogenesis of phosgene poisoning. Toxicol Ind Health. 1985;1:7–15.158. National Institute for Occupational Health and Safety. Pocket Guide to Chemical Hazards. Washington, DC: NIOSH;2004.749
Medical Aspects of Chemical Warfare159. Cucinell SA. Review of the toxicity of long-term phosgene exposure. Arch Environ Health. 1974;28:272–275.160. Polednak AP. Mortality among men occupationally exposed to phosgene in 1943–1945. Environ Res. 1980;22:357–367.161. Diller WF, Zante R. Dose-effect relations in the effects of phosgene on man and animals. Literature review. Zentralblattfuer Arbeitsmedizin, Arbeitsschutz, Prophylaxe Ergonomie. 1982;32:360–4, 366–368.162. Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clin ChimActa. 2003;333:19–39.163. Richie JP Jr, Skowronski L, Abraham P, Leutzinger Y. Blood glutathione concentrations in a large-scale human study.Clin Chem. 1996;42:64–70.164. Reed DJ, Fariss MW. Glutathione depletion and susceptibility. Pharmacol Rev. 1994;36(suppl 2):25–33.165. Pohl LR., Branchflower RV, Highest RJ, et al. The formation of diglutathionyl dithiocarbonate as a metabolite of chloroform,bromotrichloromethane, and carbon tetrachloride. Drug Metab Dispos. 1981;9:334–339.166. Fabrizi L, Taylor GW, Edwards RJ, Boobis AR. Adducts of the chloroform metabolite phosgene. Adv Exp Med Biol.2001;500:129–132.167. Anders MW, Stevens JL, Sprague RW, Shaath, Z, Ahmed AE. Metabolism of haloforms to carbon monoxide. II. In vivostudies. Drug Metab Dispos. 1978:6:556–560.168. Sciuto AM, Strickland PT, Kennedy TP, Gurtner GH. Postexposure treatment with aminophylline protects againstphosgene-induced acute lung injury. Exp Lung Res. 1997;23:317–332.169. Sciuto AM, Hurt HH. Therapeutic treatments of phosgene-induced lung injury. Inhal Toxicol. 2004;16:565–580.170. Sciuto AM. Assessment of early acute lung injury in rodents exposed to phosgene. Arch Toxicol. 1998;72:283–288.171. Sciuto AM, Cascio MB, Moran TS, Forster JS. The fate of antioxidant enzymes in bronchoalveolar lavage fluid over 7days in mice with acute lung injury. Inhal Toxicol. 2003;15:675–685.172. Kubic VL, Anders MW. Metabolism of carbon tetrachloride to phosgene. Life Sci. 1980;26:2151–2155.173. Gwilt PR, Radick LE, Li XY, Whalen JJ, Leaf CD. Pharmacokinetics of 2-oxothiazolidine-4-carboxylate, a cysteineprodrug, and cysteine. J Clin Pharmacol. 1998;38:945–950.174. Pastore A, Massoud R, Motti C, et al. Fully automated assay for total homocysteine, cysteine, cysteinylglycine, glutathione,cysteamine and 2-mercaptopropionylglycine in plasma and urine. Clin Chem. 1998;44:825–832.175. Boettcher B, Meister A. Synthesis of L-2-oxothiazolidine-4-carboxylic acid. Anal Biochem. 1984;138:449–450.176. Porta P, Aebi S, Summer K, Lauterburg BH. L-2-oxothiazolidine-4-carboxylic acid, a cysteine prodrug: pharmacokineticsand effects on thiols in plasma and lymphocytes in human. J Pharmacol Exp Ther. 1991;257:331–334.177. Kling A. Acute pulmonary edema following exposure to war gases. Comptes Rendus De L’Academie des Sciences.1933;197:1782–1784.178. Cowlen MS, Hewitt WR, Schroeder F. 2-hexanone potentiation of [14C]chloroform hepatotoxicity: covalent interactionof a reactive intermediate with rat liver phospholipid. Toxicol Appl Pharmacol. 1984;73:478–491.179. De Biasi A, Sbraccia M, Keizer J, Testai E, Vittozzi L. The regioselective binding of CHCI3 reactive intermediates tomicrosomal phospholipids. Chem Biol Interact. 1992;85:229–242.180. Guastadisegni C, Guidoni L, Balduzzi M, Viti V, Di Consiglio E, Vittozzi L. Characterization of a phospholipid adductformed in Sprague Dawley rats by chloroform metabolism: NMR studies. J Biochem Mol Toxicol. 1998;12:93–102.750
Page 3 and 4:
The Coat of Arms1818Medical Departm
Page 5:
Textbooks of Military MedicinePubli
Page 8 and 9:
MEDICAL ASPECTS o fCHEMICAL WARFARE
Page 10 and 11:
ContentsContributorsForeword by The
Page 12 and 13:
ContributorsMICHAEL ADLER, PhDResea
Page 14 and 15:
DONALD M. MAXWELL, MSResearch Chemi
Page 16 and 17:
ForewordThe US military has been co
Page 18 and 19:
PrefaceA significant concern for th
Page 20:
PrologueThe original edition of Med
Page 23 and 24:
xxii
Page 25 and 26:
Medical Aspects of Chemical Warfare
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 178 and 179:
Nerve AgentsChapter 5NERVE AGENTSFR
Page 180 and 181:
Nerve AgentsAbout 10,000 to 30,000
Page 182 and 183:
Nerve Agentsphorofluoridate (DFP) w
Page 184 and 185:
Nerve AgentsFig. 5-2. This schemati
Page 186 and 187:
Nerve AgentsExhibit 5-1 continuedis
Page 188 and 189:
Nerve Agentsactivity but only 15% t
Page 190 and 191:
Nerve AgentsTABLE 5-3CHEMICAL, PHYS
Page 192 and 193:
Nerve AgentsTABLE 5-4EFFECTS OF EXP
Page 194 and 195:
Nerve Agentsaffecting the other eye
Page 196 and 197:
Nerve Agentsmay cause severe rhinor
Page 198 and 199:
Nerve Agentsof jerks and tremor.Cen
Page 200 and 201:
Nerve Agentsand they were decreased
Page 202 and 203:
Nerve Agentsnerve agent toxicity on
Page 204 and 205:
Nerve Agentspatient. Decontaminatio
Page 206 and 207:
Nerve AgentsFig. 5-5. The Mark I ki
Page 208 and 209:
Nerve Agentsadministered intramuscu
Page 210 and 211:
Nerve Agentsthat hydroxamine reacti
Page 212 and 213:
Nerve AgentsOral administration may
Page 214 and 215:
Nerve AgentsTABLE 5-7RECOMMENDED TH
Page 216 and 217:
Nerve Agentsimpairment such as whee
Page 218 and 219:
Nerve Agentssuboptimal, manner. The
Page 220 and 221:
Nerve Agentsthan those who did not.
Page 222 and 223:
Nerve Agentssible for binding nerve
Page 224 and 225:
Nerve Agentsfor comparison was not
Page 226 and 227:
Nerve AgentsTABLE 5-11EFFECTS OF PY
Page 228 and 229:
Nerve Agentstivity of smooth muscle
Page 230 and 231:
Nerve Agents38. Grob D, Lilienthal
Page 232 and 233:
Nerve Agents77. McDonough JH, Shih
Page 234 and 235:
Nerve Agents117. McLeod CG Jr, Sing
Page 236 and 237:
Nerve Agents154. Tryphonas l, Veino
Page 238 and 239:
Nerve Agents193. Funckes AJ. Treatm
Page 240 and 241:
Nerve Agents235. Suzuki T, Morita H
Page 242:
Nerve Agents274. Pellegrini JE, Bak
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
PROCESSMedical Aspects of Chemical
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455 and 456:
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
Page 463 and 464:
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
Page 477 and 478:
Page 479 and 480:
Page 481 and 482:
Page 483 and 484:
Page 485 and 486:
Page 487 and 488:
Page 489 and 490:
Page 491 and 492:
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
Page 499 and 500:
Page 501 and 502:
Page 503 and 504:
Page 505 and 506:
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
Page 523 and 524:
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 534 and 535:
Triage of Chemical CasualtiesChapte
Page 536 and 537:
Triage of Chemical Casualtiesreceiv
Page 538 and 539:
Triage of Chemical Casualtiesentran
Page 540 and 541:
Triage of Chemical Casualtiescatego
Page 542 and 543:
Triage of Chemical CasualtiesIn a f
Page 544 and 545:
Triage of Chemical Casualtiesnose)
Page 546 and 547:
Triage of Chemical CasualtiesWith n
Page 548 and 549:
Triage of Chemical Casualties14. Sa
Page 550 and 551:
Decontamination of Chemical Casualt
Page 552 and 553:
Page 554 and 555:
Page 556 and 557:
Page 558 and 559:
Page 560 and 561:
Page 562 and 563:
Page 564 and 565:
Page 566 and 567:
Page 568 and 569:
Page 570 and 571:
Page 572 and 573:
Page 574 and 575:
Page 576 and 577:
Page 578 and 579:
Page 580:
Page 583 and 584:
Page 585 and 586:
Page 587 and 588:
Page 589 and 590:
Page 591 and 592:
Page 593 and 594:
Page 595 and 596:
Page 597 and 598:
Page 599 and 600:
Page 601 and 602:
Page 603 and 604:
Page 605 and 606:
Page 607 and 608:
Page 609 and 610:
Page 611 and 612:
Page 613 and 614:
Page 615 and 616:
Page 617 and 618:
Page 619 and 620:
Page 621 and 622:
Page 623 and 624:
Page 625 and 626:
Page 627 and 628:
Page 629 and 630:
Page 631 and 632:
Page 633 and 634:
Page 635 and 636:
Page 637 and 638:
Page 639 and 640:
Page 641 and 642:
Page 643 and 644:
Page 645 and 646:
Page 647 and 648:
Page 649 and 650:
Page 651 and 652:
Page 653 and 654:
Page 655 and 656:
Page 657 and 658:
Page 659 and 660:
Page 661 and 662:
Page 663 and 664:
Page 665 and 666:
Page 667 and 668:
Page 669 and 670:
Page 671 and 672:
Page 673 and 674:
Page 675 and 676:
Page 677 and 678:
Page 679 and 680:
Page 681 and 682:
Page 683 and 684:
Page 685 and 686:
Page 687 and 688:
Page 689 and 690:
Page 691 and 692:
Page 693 and 694:
Page 695 and 696:
Page 697 and 698:
Page 699 and 700:
Page 701 and 702:
Page 703 and 704:
Page 705 and 706:
Page 707 and 708:
Page 709 and 710:
Page 711 and 712:
Page 713 and 714:
Page 715 and 716:
Page 717 and 718:
Page 719 and 720:
Page 721 and 722: Medical Aspects of Chemical Warfare
Page 747 and 748: • Analyze using GC-MS with methan
Page 771: Medical Aspects of Chemical Warfare
Page 798 and 799: Abbreviations and AcronymsAbBreviat
Page 800: Abbreviations and AcronymsPADPRP: p
Page 823 and 824:
Page 825 and 826:
Page 827 and 828:
Page 829 and 830:
Page 831 and 832:
Page 833 and 834:
Page 835 and 836:
Page 837 and 838:
Page 839 and 840:
Page 841 and 842:
Page 843 and 844:
Page 845:
show all

Medical Aspects of Chemical Warfare (2008) - The Black Vault

Create successful ePaper yourself

Delete template?

Save as template?